Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer. We show 57 historical shares outstanding datapoints in our EXAS shares outstanding history coverage, used to compute EXAS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing EXAS market cap history over the course of time is important for investors
interested in comparing EXAS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of EXAS versus a peer is one thing; comparing
EXAS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like EXAS can fluctuate over the course of history.
With this page we aim to empower investors researching EXAS by allowing them to research the EXAS market cap history. |
Free EXAS Email Alerts:
Video: The Importance of Market Cap
